
Novartis’ investigational heart failure drug LCZ696 has been handed a Promising Innovative Medicine designation (PIM) after showing that it significantly …
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour

